# Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

> **NCT01771107** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- AIDS-Related Hodgkin Lymphoma
- Ann Arbor Stage II Hodgkin Lymphoma
- Ann Arbor Stage IIA Hodgkin Lymphoma
- Ann Arbor Stage IIB Hodgkin Lymphoma
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage IIIA Hodgkin Lymphoma
- Ann Arbor Stage IIIB Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- Ann Arbor Stage IVA Hodgkin Lymphoma
- Ann Arbor Stage IVB Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- HIV Infection

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Dacarbazine
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Pharmacological Study
- **DRUG:** Vinblastine

## Key facts

- **NCT ID:** NCT01771107
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-08
- **Primary completion:** 2021-10-15
- **Final completion:** 2024-03-21
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01771107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01771107, "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT01771107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*